论文部分内容阅读
目的探讨125I粒子组织间植入治疗前列腺癌的临床价值。方法在经直肠B超引导定位下,经会阴部穿刺前列腺125I粒子植入治疗前列腺癌5例,其中3例合并骨转移。结果5例手术均顺利,平均植入125I粒子40例,平均手术时间75min,平均住院时间6d。术后随访3￣11个月,平均5个月,完全反应3例,部分反应1例,病情恶化1例。PSA无进展生存率为80%(4/5),无严重并发症发生。结论125I粒子组织间植入治疗前列腺癌是一种安全、创伤小、并发症低且疗效肯定的微创方法。
Objective To investigate the clinical value of 125I interstitial implantation in the treatment of prostate cancer. Methods In the transrectal B-guided localization, 5 cases of prostate cancer were treated with transplanted prostate 125I through the perineum, and 3 cases were accompanied with bone metastasis. Results All the five cases were performed smoothly with an average of 125I particles in 40 cases. The average operation time was 75 minutes and the average hospitalization time was 6 days. The patients were followed up for 3 to 11 months, with an average of 5 months. There were 3 cases of complete response, 1 case of partial response and 1 case of deterioration. PSA progression-free survival rate was 80% (4/5), no serious complications. Conclusion 125I implantation of interstitial tissue in the treatment of prostate cancer is a safe, less invasive, low complication and efficacy of minimally invasive method.